PMID- 35136724
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2450-131X (Print)
IS  - 2224-4018 (Electronic)
IS  - 2224-4018 (Linking)
VI  - 9
IP  - 4
DP  - 2021 Dec 1
TI  - Lung adenocarcinoma-specific three-integrin signature contributes to poor 
      outcomes by metastasis and immune escape pathways.
PG  - 249-263
LID - 10.2478/jtim-2021-0046 [doi]
AB  - BACKGROUND: Inhibitors targeting integrins (ITGs) are applied as a novel strategy 
      for cancers including lung cancer; however, the heterogeneity of ITG subunits 
      might explain why ITG-targeted inhibitors only show limited efficacy for a small 
      group of lung cancer patients. MATERIALS AND METHODS: RNA-Seq data of lung 
      adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients were 
      obtained from the TCGA database. Cox regression analysis was performed to 
      construct the prognostic signature and generate the nomogram combined with 
      pathologic stages (pStage). GEO datasets were used for verification. The related 
      biological functions were analyzed by Gene Set Enrichment Analysis (GSEA) 
      software and the TIMER database. RESULTS: By Cox regression analysis of 30 ITG 
      subunits, ITG subunit alpha 5 (ITGA5), ITG subunit alpha 6 (ITGA6), and ITG 
      subunit alpha L (ITGAL) were identified as the prognostic factors in LUAD, which 
      were included in the construction of a LUAD-specific 3-ITG signature. Following 
      the calculation of risk score (RS) of each patient based on 3-ITG signature, 
      patients with high RS in LUAD were found to exhibit worse prognosis, especially 
      in early stage. Nomogram combined with RS and pStage could predict the prognosis 
      of LUAD patients accurately. Mechanism exploration by GSEA showed that 
      metastasis-related microenvironmental pathways were significantly enriched in the 
      high-RS group. An elevated expression of ITGA5 was mainly associated with the 
      promotion of cell migration and invasion, while the high expression of ITGAL had 
      a strong positive correlation with the capability of recognizing and killing 
      cancer cells. CONCLUSIONS: Three-ITG signature could improve the prediction 
      ability combined with pStage in LUAD and might contribute to poor prognosis by 
      metastasis and immune escape-related pathways.
CI  - (c) 2021 Yizhe Wang et al., published by Sciendo.
FAU - Wang, Yizhe
AU  - Wang Y
AD  - Department of Respiratory and Infectious Disease of Geriatrics, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
FAU - Hou, Kezuo
AU  - Hou K
AD  - Department of Medical Oncology, The First Hospital of China Medical University, 
      Shenyang 110001, Liaoning Province, China.
AD  - Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
AD  - Liaoning Province Clinical Research Center for Cancer, The First Hospital of 
      China Medical University, Shenyang 110001, Liaoning Province, China.
FAU - Jin, Yue
AU  - Jin Y
AD  - Department of Medical Oncology, The First Hospital of China Medical University, 
      Shenyang 110001, Liaoning Province, China.
AD  - Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
AD  - Liaoning Province Clinical Research Center for Cancer, The First Hospital of 
      China Medical University, Shenyang 110001, Liaoning Province, China.
FAU - Bao, Bowen
AU  - Bao B
AD  - Department of Medical Oncology, The First Hospital of China Medical University, 
      Shenyang 110001, Liaoning Province, China.
AD  - Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
AD  - Liaoning Province Clinical Research Center for Cancer, The First Hospital of 
      China Medical University, Shenyang 110001, Liaoning Province, China.
FAU - Tang, Shiying
AU  - Tang S
AD  - Department of Medical Oncology, The First Hospital of China Medical University, 
      Shenyang 110001, Liaoning Province, China.
AD  - Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
AD  - Liaoning Province Clinical Research Center for Cancer, The First Hospital of 
      China Medical University, Shenyang 110001, Liaoning Province, China.
FAU - Qi, Jianfei
AU  - Qi J
AD  - Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of 
      Maryland, Baltimore, MD 21201, USA.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Respiratory and Infectious Disease of Geriatrics, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
FAU - Che, Xiaofang
AU  - Che X
AD  - Department of Medical Oncology, The First Hospital of China Medical University, 
      Shenyang 110001, Liaoning Province, China.
AD  - Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
AD  - Liaoning Province Clinical Research Center for Cancer, The First Hospital of 
      China Medical University, Shenyang 110001, Liaoning Province, China.
FAU - Liu, Yunpeng
AU  - Liu Y
AD  - Department of Medical Oncology, The First Hospital of China Medical University, 
      Shenyang 110001, Liaoning Province, China.
AD  - Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
AD  - Liaoning Province Clinical Research Center for Cancer, The First Hospital of 
      China Medical University, Shenyang 110001, Liaoning Province, China.
FAU - Hu, Xuejun
AU  - Hu X
AD  - Department of Respiratory and Infectious Disease of Geriatrics, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
FAU - Zheng, Chunlei
AU  - Zheng C
AD  - Department of Medical Oncology, The First Hospital of China Medical University, 
      Shenyang 110001, Liaoning Province, China.
AD  - Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First 
      Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
AD  - Liaoning Province Clinical Research Center for Cancer, The First Hospital of 
      China Medical University, Shenyang 110001, Liaoning Province, China.
LA  - eng
PT  - Journal Article
DEP - 20211231
PL  - Poland
TA  - J Transl Int Med
JT  - Journal of translational internal medicine
JID - 101673826
PMC - PMC8802404
OTO - NOTNLM
OT  - biomarkers
OT  - integrin
OT  - lung adenocarcinoma
OT  - prognosis
OT  - risk factors.
COIS- The authors have no conflicts of interest to declare.
EDAT- 2022/02/10 06:00
MHDA- 2022/02/10 06:01
PMCR- 2021/12/31
CRDT- 2022/02/09 05:55
PHST- 2022/02/09 05:55 [entrez]
PHST- 2022/02/10 06:00 [pubmed]
PHST- 2022/02/10 06:01 [medline]
PHST- 2021/12/31 00:00 [pmc-release]
AID - jtim-2021-0046 [pii]
AID - 10.2478/jtim-2021-0046 [doi]
PST - epublish
SO  - J Transl Int Med. 2021 Dec 31;9(4):249-263. doi: 10.2478/jtim-2021-0046. 
      eCollection 2021 Dec 1.